07:00 , May 27, 2013 |  BC Week In Review  |  Company News

GlaxoSmithKline, U.S. Department of Health and Human Services infectious news

HHS's Biomedical Advanced Research and Development Authority (BARDA) awarded GlaxoSmithKline $40 million for an initial 18-month period to develop GSK's portfolio of antibacterial candidates to treat illnesses caused by bioterrorism agents and antibiotic-resistant bacteria. If...
08:00 , Nov 19, 2012 |  BioCentury  |  Regulation

Antibiotics reset

There is a consensus among the U.S. government, industry and the medical community that the failure of antibiotic development to keep pace with the evolution of bacterial pathogens constitutes a public health crisis, and that...
08:00 , Feb 13, 2012 |  BC Week In Review  |  Company News

Dako sales and marketing update

Dako launched its HER2 IQFISH pharmDx and TOP2A IQFISH pharmDx tests in Europe to identify targeted treatments for cancer patients. The fluorescent in situ hybridization (FISH) assays are designed to detect mutations in the HER2...
07:00 , Aug 22, 2011 |  BC Week In Review  |  Clinical News

TOP2A FISH detection kit regulatory update

China's State Food and Drug Administration (SFDA) approved China Medical's Topoisomerase 2-alpha (TOP2A) FISH detection kit. China Medical Technologies Inc. (NASDAQ:CMED), Beijing, China   Product: TOP2A FISH detection kit   Business: Diagnostic  ...
07:00 , Aug 15, 2011 |  BC Week In Review  |  Company News

China Medical Technologies, Leica Microsystems deal

Leica Microsystems' Biosystems division and China Medical will co-develop and commercialize automated fluorescence in situ hybridization (FISH) kits for tissue sample tests to detect EGFR , EGFR2 ( HER2 ; ErbB2 ; neu) and topoisomerase...
08:00 , Nov 8, 2010 |  BC Week In Review  |  Company News

Caris Life Sciences sales and marketing update

Caris added 14 biomarkers to its Target Now breast cancer panel of biomarkers, which is used to profile tumors in breast cancer patients. Biomarkers added to the panel include: transducin-like enhancer of split 3 (TLE3)...
07:00 , Apr 8, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Topoisomerase IIa (TOP2A) In vitro and mouse studies suggest that thiosemicarbazone-based inhibitors of TOP2A could help treat cancer. In vitro, a lead compound showed...
07:00 , Jun 4, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute lymphoblastic leukemia (ALL); acute myelogenous leukemia (AML) SET domain and mariner transposase fusion gene (SETMAR; METNASE); Topoisomerase IIa (TOP2A) Studies...
08:00 , Jan 21, 2008 |  BC Week In Review  |  Clinical News

TOP2A FISH pharmDx regulatory update

Dako received FDA clearance to market its TOP2A FISH pharmDx genetic test to assess the risk of tumor recurrence and long-term survival for patients with high-risk breast cancer. The fluorescent in situ hybridization (FISH) assay...
02:08 , Jan 15, 2008 |  BC Extra  |  Company News

FDA approves Dako's breast cancer test

FDA approved the TOP2A FISH pharmDx genetic test from Dako (Glostrup, Denmark) to assess the risk of tumor recurrence and long-term survival for patients with high-risk breast cancer. The dual probe, fluorescent in situ hybridization...